Department of Pharmacy, Valley Children's Hospital, Cancer and Blood Disorders Center, Madera, CA.
Am J Health Syst Pharm. 2020 Feb 7;77(4):277-281. doi: 10.1093/ajhp/zxz311.
The implementation of a pediatric desensitization protocol specific to etoposide in an adolescent with Hodgkin lymphoma is described.
Etoposide is part of many chemotherapy regimens used to treat malignancies in children and adults, and it is also part of the backbone of many regimens used in clinical trials. Etoposide is known to produce hypersensitivity reactions during administration. Substitution with etoposide phosphate, which has less potential for hypersensitivity reactions, is used in place of etoposide after severe hypersensitivity reactions. Etoposide desensitization protocols (EDPs) have been reported in adult patients.
The implementation of an etoposide desensitization protocol for pediatric patients is safe and helpful to prevent the elimination of etoposide from treatment protocols. The use of an EDP allowed the patient to remain on clinical trial and complete the prescribed treatment.
描述一例青少年霍奇金淋巴瘤患者中依托泊苷特异性脱敏方案的实施。
依托泊苷是许多用于治疗儿童和成人恶性肿瘤的化疗方案的一部分，也是临床试验中许多方案的骨干部分。依托泊苷在给药过程中已知会引起过敏反应。在严重过敏反应后，用过敏反应潜力较小的依托泊苷磷酸替代依托泊苷。已经有报道称成人患者采用依托泊苷脱敏方案（EDP）。
为儿科患者实施依托泊苷脱敏方案是安全的，有助于防止依托泊苷从治疗方案中被排除。EDP 的使用使患者能够继续参加临床试验并完成规定的治疗。
